Long-term ovariectomized (OVX) rats were injected in the third cerebral ventricle with 5 ,l~of the globulin fraction of an antiserum raised against a-melanocyte-stimulating hormone (a-MSH) or an equal volume of the globulin fraction of normal rabbit serum (NRS). Immunoneutralization of brain a-MSH produced an increase in the area under the secretion curve of prolactin (Prl), the amplitude of Prl pulses, and mean plasma Prl (P < 0.01). Recently, a-MSH has been found extensively throughout the brain, with high concentrations detected in axons and terminals of the hypophysiotropic area of the hypothalamus (4, 5). The cell bodies containing this peptide have been localized in the arcuate nucleus (5) and more recently in the dorsolateral region of the hypothalamus (6). Based on the distribution of this peptide and its detection in the hypophysial portal blood by a specific radioimmunoassay (RIA) (7), we evaluated the effect of this peptide on the release of anterior pituitary hormones.In recent studies we found that injection of a-MSH into the third ventricle of the brain of ovariectomized (OVX), freely moving rats produced a dose-dependent inhibition of basal and stress-induced release of prolactin (Prl) (8) and inhibited pulsatile release of luteinizing hormone (LH) (9). These effects could be blocked by prior administration of the inhibitor of catecholamine synthesis a-methyl-p-tyrosine or the dopamine receptor blocker spiroperidol (8, 9). a-MSH did not alter Prl and LH release from hemipituitaries and dispersed anterior pituitary cells incubated in vitro, which indicates that this peptide exerts its effect on Prl and LH release via an action in the hypothalamus to stimulate dopamine release, which, in turn, inhibits Prl and LH release (8,9). To determine whether the inhibitory effect of a-MSH may be physiologically relevant in the regulation of these hormones, we passively immunized rats with antisera to a-MSH.
MATERIALS AND METHODSAdult female Sprague-Dawley rats of the Holtzman strain were employed. Females were OVX to eliminate the influence of ovarian steroids and elevate gonadotropin levels. The animals were used 3-6 weeks after ovariectomy. Antiserum was delivered to the brain via a cannula implanted in the third brain ventricle (10). A Silastic cannula implanted 24 hr before the experiment in the right external jugular vein (11) was used for withdrawal of blood samples (0.25 ml). After withdrawal of every sample, the blood volume was restored by an injection of an equal volume of heparinized (20 units/ ml), physiological saline. After every four samples, erythrocytes (0.5 ml) prepared previously were injected. The cells were obtained from OVX rats the day prior to the experiment and suspended in 0.9% saline to a hematocrit of 45%.The antiserum used (KDM-1) has been fully characterized (12). Briefly, this antiserum cross-reacts on a molar basis 0.029% with corticotropin (ACTH)-(1-24), 0.004% with ACTH-(1-39), 0.001% with ACTH-(1-10), and 36% with desacetyl-a-MSH and does not cross-react at a 100 mol...